The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> April 29, 2025

Interview with the Chairman, President and CEO: Puma Biotechnology, Inc. (NASDAQ:PBYI)

Auerbach, Alan H.
Alan H. Auerbach has served as Chairman of the Board and as CEO and President of Puma Biotechnology, Inc. since its inception. Before joining Puma, Mr. Auerbach served as Founder, CEO, President and a member of the board of directors of Cougar Biotechnology, Inc., from the company’s inception in 2003 until its acquisition by Johnson & Johnson in July 2009. From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of Johnson & Johnson) for Cougar’s lead product candidate, abiraterone acetate, which was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the European Union in September 2011. Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle-capitalization biotechnology companies, with a focus on companies in the field of oncology. From August 1997 to May 1998, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-capitalization biotechnology companies. Prior to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. Mr. Auerbach currently serves as a director of Radius Health, Inc., a pharmaceutical company focused on developing new drugs for osteoporosis and women’s health. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. Profile
Word count: 1,950

TWST: Please tell us about Puma Biotechnology.

Mr. Auerbach: I’d be more than happy to. Puma is a biotech company that is dedicated to the

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
GE Aerospace (General Electric Company)
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the Chairman, President and CEO: Puma Biotechnology, Inc. (NASDAQ:PBYI)
Interview with the President and CEO: NeurAxis, Inc. (NYSEAMERICAN:NRXS)
Interview with the Chairman and CEO: Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) and Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Asymmetric Risk/Reward at Core of Multi-Asset Strategy
Dividend Growth Strategy Favors High-Quality Financials
Screening for 10% Dividend Growth Over 10 Years
ANALYST INTERVIEWS
Small Cap Med-Tech Names Are More Insulated from Tariff Fallout
Penumbra and AngioDynamics Among Top Med-Tech Sector Picks
Onshoring Drug Manufacturing Is Critical, But Not Easy
Since 1963
© The Wall Street Transcript 2016, 2025
Terms and Conditions
Privacy Policy